Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis

COVID-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran

(2022) Seyed Massood Nabavi et al.   Vaccines

Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis

(2022) Ethel Ciampi et al.   Multiple Sclerosis and Related Disorders

COVID-19 vaccine associated demyelination & its association with MOG antibody

(2022) M. Netravathi et al.   Multiple Sclerosis and Related Disorders

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021

(2021) Anat Achiron et al.   Multiple Sclerosis Journal

Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?

(2021) Caroline Papeix et al.   Multiple Sclerosis Journal

Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2

(2021) Ian McDonald et al.   npj Vaccines

Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era

(2021) Patricia K. Coyle et al.   ADVANCES IN THERAPY

Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel

(2021) Itay Lotan et al.   EUROPEAN JOURNAL OF NEUROLOGY

A case of longitudinally extensive transverse myelitis following vaccination against Covid-19

(2021) Claudia Pagenkopf et al.   JOURNAL OF NEUROIMMUNOLOGY

Vaccination and multiple sclerosis in the era of the COVID-19 pandemic

(2021) Tobias Monschein et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

(2021) Mine Durusu Tanriover et al.   LANCET

COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey

(2021) Lauren Uhr et al.   Multiple Sclerosis Journal

Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19

(2021) Shuai Chen et al.   NEUROLOGICAL SCIENCES

Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV

(2021) Mohammad Ali Sahraian et al.   VACCINE

COVID-19 Vaccination Attitudes With Neuromyelitis Optica Spectrum Disorders: Vaccine Hesitancy and Coping Style

(2021) Yafang Xu et al.   Frontiers in Neurology

Mortality of neuromyelitis optica spectrum disorders in a Chinese population

(2021) Qin Du et al.   Annals of Clinical and Translational Neurology

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

(2021) Raches Ella et al.   LANCET

Willingness to receive a COVID-19 vaccine in people with multiple sclerosis – UK MS Register survey

(2021) Yun Huang et al.   Multiple Sclerosis and Related Disorders

New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19

(2021) Yara D Fragoso et al.   Multiple Sclerosis and Related Disorders

COVID-19 and vaccination against SARS-CoV-2 in patients with neuromyelitis optica spectrum disorders

(2021) Vanja Jovicevic et al.   Multiple Sclerosis and Related Disorders

¿ Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis

(2021) Gloria Michelena et al.   Multiple Sclerosis and Related Disorders

Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases

(2021) Itay Lotan et al.   Multiple Sclerosis and Related Disorders

Post COVID-19 vaccination neuromyelitis optica spectrum disorder: Case report & MRI findings

(2021) Noor Badrawi et al.   Radiology Case Reports

COVID-19 Vaccine Frontrunners and Their Nanotechnology Design

(2020) Young Hun Chung et al.   ACS Nano

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

(2020) Gregory A Poland et al.   LANCET

Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic

(2020) Hesham Abboud et al.   Multiple Sclerosis and Related Disorders

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China

(2020) Yulan Lin et al.   PLoS Neglected Tropical Diseases

Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study

(2019) Ziyan Shi et al.   JOURNAL OF NEUROLOGY

Addressing Vaccine Hesitancy in China: A Scoping Review of Chinese Scholarship

(2019) Ronghui Yang et al.   Vaccines

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response

(2017) Jan-Patrick Stellmann et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Comparison of Propensity Score Methods and Covariate Adjustment

(2017) Markus C. Elze et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

(2016) Ilya Kister et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Health insurance affects the use of disease-modifying therapy in multiple sclerosis

(2016) Guoqiao Wang et al.   NEUROLOGY

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

(2015) Dean M. Wingerchuk et al.   NEUROLOGY

Vaccine hesitancy: Definition, scope and determinants

(2015) Noni E. MacDonald   VACCINE

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Infections and autoimmunity – friends or foes?

(2009) Shaye Kivity et al.   TRENDS IN IMMUNOLOGY